Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide

D Biasoli1, SA Kahn1, TA Cornélio1, M Furtado1,2, L Campanati1, H Chneiweiss3, V Moura-Neto1 and HL Borges*,1

Glioblastomas (GBMs) are devastating tumors of the central nervous system, with a poor prognosis of 1-year survival. This result from a high resistance of GBM tumor cells to current therapeutic options, including etoposide (VP-16). Understanding resistance mechanisms may thus open new therapeutic avenues. VP-16 is a topoisomerase inhibitor that causes replication fork stalling and, ultimately, the formation of DNA double-strand breaks and apoptotic cell death. Autophagy has been identified as a VP-16 treatment resistance mechanism in tumor cells. Retinoblastoma protein (RB) is a classical tumor suppressor owing to its role in G1/S cell cycle checkpoint, but recent data have shown RB participation in many other cellular functions, including, counterintuitively, negative regulation of apoptosis. As GBMs usually display an amplification of the EGFR signaling involving the RB protein pathway, we questioned whether RB might be involved in mechanisms of resistance of GBM cells to VP-16. We observed that RB silencing increased VP-16-induced DNA double-strand breaks and p53 activation. Moreover, RB knockdown increased VP-16-induced apoptosis in GBM cell lines and cancer stem cells, the latter being now recognized essential to resistance to treatments and recurrence. We also showed that VP-16 treatment induced autophagy, and that RB silencing impaired this process by inhibiting the fusion of autophagosomes with lysosomes. Taken together, our data suggest that RB silencing causes a blockage on the VP-16-induced autophagic flux, which is followed by apoptosis in GBM cell lines and in cancer stem cells. Therefore, we show here, for the first time, that RB represents a molecular link between autophagy and apoptosis, and a resistance marker in GBM, a discovery with potential importance for anticancer treatment.

Cell Death and Disease (2013) 4, e767; doi:10.1038/cddis.2013.283; published online 15 August 2013

Subject Category: Cancer
transcriptional repression complexes to allow G1 to S phase transition.\textsuperscript{19} Knudsen et al.\textsuperscript{29} showed that RB also induces S-phase arrest, triggered by the intra S-phase checkpoint in the presence of DNA-damaging agents, such as cisplatin and VP-16. RB also participates in other cellular processes, such as terminal cell differentiation and maintenance of genetic stability.\textsuperscript{18,21}

Counterintuitively, evidences from the literature have also suggested that RB can exert an anti-apoptotic function. Haas-Kogan et al.\textsuperscript{22} showed that the expression of RB decreased radiation-induced apoptosis in the osteosarcoma RB-deficient cells Saos-2. It has also been shown that RB is cleaved by caspases during apoptosis induced by VP-16 and tumor necrosis factor-\alpha (TNF-\alpha).\textsuperscript{23,24} The caspase-resistant RB, engineered in mice, inhibits inflammation-induced cell death \textit{in vivo}.\textsuperscript{25,26} and the TNF receptor 1 triggered apoptosis in mouse embryonic fibroblasts (MEFs).\textsuperscript{25} Moreover, the expression of caspase-resistant RB in cerebellar granular neurons reduces apoptosis caused by potassium deprivation.\textsuperscript{27} In addition, MEFs displaying a conditional knockout of RB are more susceptible to VP-16 and cisplatin-induced cell death.\textsuperscript{20} Chau et al.\textsuperscript{28} have further demonstrated, by using targeted mutations on the \textit{RB1} gene, that RB inhibition of VP-16-induced apoptosis is independent of RB growth suppression function.

The RB pathway is altered in 70% of human cancer types.\textsuperscript{29} In GBM, this pathway is altered in 78% of the cases, although mutations and homozygous deletions of the \textit{RB1} gene itself appear in only 11% of them.\textsuperscript{30} Instead, the RB pathway is preferentially altered at components that lead to RB inactivation by hyperphosphorylation, which leads to suppression of its cell cycle blocker function.\textsuperscript{19}

In this work, we tested whether RB, even inactivated by hyperphosphorylation, could promote resistance to VP-16 in GBM and in GBM cancer stem cells, which are more resistant to chemo- and radiotherapy\textsuperscript{2,23–26}. We show here, for the first time, that RB is involved in the regulation of an interplay between autophagy and apoptosis, and promotes resistance of GBM cells to VP-16. Moreover, these results show that the hyperphosphorylated RB, found in GBM, is not only a determinant for the high levels of cell proliferation, but is also a determinant for chemotherapy resistance.

\textbf{Results}

\textbf{RB knockdown using RNAi in GBM cell lines and in GSCs.} To investigate the role of RB protein in the response of GBM cells to VP-16, we chose two GBM cell lines that display hyperphosphorylated RB (Supplementary Figure S1): U87 MG, an American Type Culture Collection (ATCC) cell line that does not express the CDK inhibitor p16\textsuperscript{25}, and GBM95, isolated in our laboratory through biopsy of a recurrent GBM tumor\textsuperscript{26} and the GBM stem cell (GSC) line OB1 (refs 37,38). By Immunoblotting analysis we were able to detect similar levels of total RB protein in GBM cell lines U87 and GBM95, and in GSC OB1 (Supplementary Figure S1A). Besides, RB phosphorylation at serine 807/811 was detected in the GBM cell lines and in GSCs (Supplementary Figure S1B). This confirms, as expected\textsuperscript{26}, that the cell lines used in this work present hyperphosphorylated RB.

The efficiency of RB knockdown was of ~70% in both GBM cell lines, and ~80% in GSCs (Figures 1a–d). Twenty-four hours after transfection, 30% (Figures 1a and b) and 20% (Figures 1c and d) of residual RB was detected by western blotting in the silenced RB group (siRNA-RB) in comparison with the off-target non-silenced group (siRNA-Neg), in the GBM cell lines and in GSC OB1, respectively (Figures 1a–d). In all subsequent experiments, VP-16 treatment was initiated 24 h post-small interfering RNA (siRNA) transfection.

\textbf{RB knockdown increased VP-16-induced apoptosis.} To test whether RB knockdown could increase VP-16-induced apoptosis, we compared the percentage of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-positive cells between silenced and non-silenced groups, 24 h after VP-16 treatment, in U87 and GBM95 cells. The concentration of 1\textmu M of VP-16 was chosen, as it decreased cell viability to ~50% in both U87 and GBM95 cell lines, as seen in a VP-16 dose–response curve 24 h after treatment (Figure 1e). Twenty-four hours after 1\textmu M of VP-16 treatment, U87 cell cultures showed ~2.5 times more TUNEL-positive cells in the RB-silenced group compared with the off-target non-silenced group (siRNA-Neg) (Figures 2a and c). As for GBM95 cells, the percentage of TUNEL-positive cells increased fourfold in the silenced RB group (Figures 2a and c). In both the GBM cell lines tested, RB knockdown also increased the cell death level measured by ethidium homodimer incorporation, which is thought to occur only in cells with disrupted plasma membrane\textsuperscript{39} (data not shown). Therefore, in both GBM cell lines tested, RB knockdown was capable of potentiating VP-16 treatment through increased apoptosis.

GSCs have now been positioned in a centre stage for the development of cancer therapies because of its capacity for self-renewal and generation of varied differentiated cell types within a tumor mass.\textsuperscript{31} As we observed that RB knockdown increased VP-16-induced apoptosis in GBM cell lines, we wondered whether the same would be observed in GSCs.

To test this hypothesis, we used the GSC line OB1 refs \textsuperscript{37,38}, which has a high capacity to self-renew. This cell line expresses Nestin, a neural stem cell marker, SOX-2, an embryonic stem cell marker and CD133, a GSC marker (Supplementary Figure S2). We silenced RB in OB1 cells (Figures 1c and d) and compared the percentage of TUNEL-positive cells between silenced and non-silenced groups after VP-16 treatment. As seen in the VP-16 dose–response curves (Figure 1e), OB-1 GSCs are more resistant to VP-16 treatment than the GBM cell lines tested (U87 and GBM95); therefore, in this assay we used VP-16 at a concentration of 30\textmu M, as it resulted in 80% of OB1 survival (Figure 1e).

Our results showed that RB knockdown increased the percentage of TUNEL-positive OB1 cells by threefold after VP-16 treatment, resulting in over 85% of TUNEL-positive cells (Figures 2b and d). This result shows that RB knockdown increases VP-16-induced apoptosis in GSCs in a similar manner than that previously observed for GBM cells (Figure 2c). Cleaved caspase-3 immunostaining confirmed the effectiveness of RB silencing to increase VP-16-induced apoptotic cell death (Figure 2e and Supplementary Figure S3). Moreover, RB silencing increased p53 phosphorylation at
serine 15 residue (Figure 2f), which leads to p53 accumulation and induction of apoptosis, suggesting that RB knockdown induced an increase in p53-dependent apoptosis. RB knockdown increased VP-16-induced apoptosis even in a p53-independent manner. To test whether RB knockdown could have a broader effect on GBM cells, we used three other GBM cell lines: A172, T98G, which is p53 mutated, and U373, which expresses low levels of RB. We performed RB knockdown in these cell lines (Figure 3c) and compared the percentage of TUNEL-positive cells between silenced (siRNA-RB plus VP-16) and non-silenced (siRNA-Neg plus VP-16) groups after VP-16 treatment. U373 cells, which naturally present lower levels of RB expression (Figure 3c), exhibited the highest sensitivity to VP-16-induced apoptosis (Figures 3a and b). Furthermore, RB knockdown in U373 cells increased even more the percentage of TUNEL-positive cells (Figures 3a and b). These results further confirm that lower levels of RB expression favors VP-16-induced apoptosis. RB knockdown also increased the levels of TUNEL-positive nuclei in A172 and even in T98G cells (Figures 3a and b). This later cell line express mutant p53, which is not activated, as measured by serine 15 phosphorylation, in the presence of VP-16 (Supplementary Figure S4). These results suggest that RB knockdown is able to increase VP-16-induced apoptosis independently of p53 activation, although the combinatory treatment is more efficient in cells that express wild-type p53. This data set shows that RB knockdown is able to increase VP-16-induced apoptosis in a wide range of genetic backgrounds of GBM cells.

RB knockdown increased VP-16-induced DNA double-strand breaks. VP-16 generates DNA double-strand breaks that accumulate and ultimately trigger apoptosis.
Therefore, we questioned whether the increase in VP-16-induced apoptosis, seen after RB knockdown, could be due to an increase in DNA double-strand breaks. To test that, we compared the levels of γ-H2AX staining between RB-silenced and non-silenced groups. γ-H2AX is a modified histone, which is γ-phosphorylated after DNA double-strand breaks. Our results showed that incubation with VP-16 for 1 h increased the fluorescence intensity of γ-H2AX immunostaining in both GBM cell lines tested (Figures 4a and b). However, the increase in γ-H2AX immunostaining induced by VP-16 was significantly higher in the RB-silenced group (siRNA-RB plus VP-16) when compared with the siRNA off-target control group (siRNA-Neg plus VP-16), suggesting that VP-16 was more efficient to induce DNA damage in the RB-silenced group (Figure 4c).

RB knockdown disrupted VP-16-induced autophagic process. It has been postulated that autophagy may be a resistance mechanism of tumor cells in the presence of an apoptotic stimulus. For this reason, we decided to investigate whether VP-16 treatment could induce autophagy in GBM cells, and whether RB silencing could interfere with it. As autophagy is a multi-step process regulated at different points, we performed experiments to evaluate separate stages of this process.

First, we measured the expression of Beclin-1, a marker of autophagy induction, using starving cells as positive controls. As shown in Figure 5a, VP-16 treatment increased Beclin-1...
expression in both non-silenced (siRNA-Neg plus VP-16) and silenced (siRNA-RB plus VP-16) groups, in the same manner, indicating that RB silencing does not alter VP-16-dependent autophagy induction. Next, we compared the levels of the lipidated form of microtubule-associated protein 1A/1B-light chain 3 (LC-3 II), among our experimental groups. In the autophagic process, LC-3 I is lipidated, becoming LC-3 II, which is incorporated into autophagosome membranes, where it is degraded when autophagosomes fuse with lysosomes to form autophagolysosomes. As seen in Figure 5a, VP-16 treatment increased, in all groups, the level of LC-3 II, which is detected at 14 kDa. Furthermore, the level of LC-3 II was higher in the silenced (siRNA-RB plus VP-16) than in the non-silenced (siRNA-Neg plus VP-16) group (Figure 5a). This could be due to a higher level of LC3-II formation, or to a lower level of LC3-II degradation in autophagolysosomes. As autophagolysosomes are acid compartments, we compared, through acridine orange labeling, the formation of acid vesicles, a final step in autophagic process. As noticed from Figures 5b and c, the increase in red fluorescence, depicting acid vesicles, is approximately two times lower in the silenced group (siRNA-RB plus VP-16) when compared with that of the non-silenced group (siRNA-Neg plus VP-16) in both cell lines, showing that VP-16-induced acid vesicle formation is lower in the RB-silenced group. This result, in conjunction with the accumulation of LC-3 II, suggests that RB silencing blocks VP-16-induced autophagic flux in its final steps. Electron microscopy data corroborates this hypothesis (Figure 5d), as it shows that the VP-16-induced autophagic vacuoles in the RB-silenced group (siRNA-RB plus VP-16) are frequently filled with electron dense material, similar to the cytosol (indicated by white arrows), possibly representing vacuoles containing non-degraded material due to autophagic flux blockage. The non-silenced group (siRNA-Neg plus VP-16) most frequently presents clear vacuoles (indicated by black arrows), which could represent vacuoles with total digested content.

RB knockdown blocked VP-16-induced autophagic flux. To test whether RB knockdown in fact blocked VP-16-induced autophagic flux in its final steps, we performed western blotting experiments to detect p62 levels. This protein is degraded in autophagolysosomes and, thus, its accumulation indicates a blockage in autophagic flux. Our results showed that VP-16 treatment induced a significant reduction of p62 levels in U87 cells (siRNA-Neg plus VP-16), which is expected when autophagy is induced. On the contrary, RB knockdown significantly increased p62 levels.

Figure 3  RB knockdown increased apoptosis induced by VP-16 in different GBM cell lines. (a) Representative images of three independent experiments of TUNEL assay (red) using A172, T98G and U373 cells after 24 h of 1 μM VP-16 treatment; experimental groups as indicated. Nuclei were stained with DAPI. Arrows indicate TUNEL-positive cells. Scale bar = 10 μm. (b) Percentage of TUNEL-positive A172 (checkered bars), T98G (horizontal striped bars) and U373 (gray bars) cells 24 h after 1 μM VP-16 treatment; experimental groups as indicated. **P<0.01 and ***P<0.005 by ANOVA and Tukey’s post test. Data are represented as mean and S.E.M. of three independent experiments. (c) Representative western Blotting image of three independent experiments, comparing the levels of RB protein between non-silenced (siRNA-Neg) and silenced groups (siRNA-RB) of A172, T98G and U373 cell lines. α-Tubulin was used as loading control.
(siRNA-RB plus VP-16) (Figures 6c and e), thus confirming that RB knockdown blocked VP-16-induced autophagic flux.

To test whether the autophagic blockage induced by RB knockdown would be at the stage of autophagosomes fusion to lysosomes, we obtained confocal images of double staining to localize LC3, an autophagosome marker, and LAMP 1, a lysosome marker. Our results showed that VP-16 treatment induced the colocalization of LAMP 1 and LC3, and that RB knockdown decreased this colocalization (Figures 6a, a’ and b). Therefore, RB knockdown blocks VP-16-induced autophagic flux by somehow inhibiting the fusion of autophagosomes with lysosomes.

It has been shown that p53 induces the expression of damage-regulated autophagy modulator (DRAM).46 DRAM is a lysosomal protein that has been shown to regulate autophagy and is necessary for apoptosis.46 To test whether DRAM activity is affected by RB knockdown, we performed western blotting experiments to detect the levels of vaccinia-related kinase 1 (VRK1), which is downregulated by DRAM,47 as a way to indirectly analyze the activation of DRAM. Our results showed that VP-16 reduced the levels of VRK1 in U87 cells, and that RB knockdown significantly reduced it even more (Figures 6d and e). These results are consistent with RB knockdown increasing VP-16-induced DRAM activation.

Discussion

RB is a classical tumor suppressor owing to its role as a regulator of G1 to S phase checkpoint; however, novel functions exerted by this protein are being described in the literature, including the negative regulation of apoptosis.18,22-27 Here we showed that RB, even in its hyperphosphorylated state, when it is inactivated for its classical cell cycle blocker function, is able to block apoptosis

**Figure 4** RB knockdown increased DNA double-strand breaks induced by VP-16. (a) Representative images of three independent experiments of immunofluorescence staining with anti-γH2AX antibody (red) after 1 h of VP-16 treatment in U87 cells; experimental groups as indicated. Nuclei were stained with DAPI. Scale bar = 10 μm. (b) Histogram shows fold changes of red fluorescence intensity (mean red fluorescence/total cell number) over siRNA-Neg control group; after 1 h of VP-16 treatment of U87 (black bars) and GBM95 (white bars) cells; experimental groups as indicated. ***P < 0.005 by ANOVA and Tukey’s post test. Data are represented as mean and S.E.M. of three independent experiments. (c) Representative γH2AX immunoblot of U87 and GBM95 cells 1 h post-VP-16 treatment; experimental groups as indicated. α-Tubulin was used as loading control.
in GBM cells. This result shows that RB anti-apoptotic function is independent from its cell cycle function, in accordance with what Chau et al.\textsuperscript{28} have shown. Furthermore, the presence of hyperphosphorylated RB in tumor cells, such as GBM, may not only allow high rates of cellular proliferation, but also resistance to therapy. The involvement of RB in VP-16 treatment response in GBM cells has not been explored so far. Our results showed that RB knockdown increased VP-16-induced apoptosis in GBMs, as well as in GSCs. It has already been described that conditional RB knockdown increases susceptibility of MEFs to VP-16-induced cell death.\textsuperscript{29} Here we showed that the reduction of RB expression can also sensitize GBMs and GSCs to VP-16-induced apoptosis, demonstrating that RB anti-apoptotic function is still maintained in these tumor cells. The fact that we also observed this phenomenon in a recurrent GBM cell line (GBM95)\textsuperscript{36} increases the potential of clinical translation, as VP-16 treatment is mostly reserved for recurrent GBM patients.\textsuperscript{6}

In this work we also showed that RB knockdown increased DNA double-strand breaks induced by VP-16 treatment in GBM cells, suggesting that RB normally blocks VP-16-induced DNA damage. Bosco et al.\textsuperscript{48} have shown that RB conditional

**Figure 5** RB knockdown impaired VP-16-induced autophagy. (a) Representative Beclin-1 and LC-3 immunoblots for U87 cells 24 h post-VP-16 treatment (1 \(\mu\)M); experimental groups as indicated. \(\alpha\)-Tubulin was used as loading control. Starved cells were used as positive control of autophagy induction. Starvation was induced by incubating the cells for 3 h in Krebs-Ringer buffer. (b) Graphic shows changes in intensity of red fluorescence (indicating acid vesicles labeled with acridine orange) in U87 (black bars) and GBM95 (white bars) cells after 24 h of VP-16 treatment (1 \(\mu\)M). Changes in red fluorescence were represented as fold increase (mean red fluorescence/total cell number) over control (siRNA-Neg group); experimental groups as indicated. **\(P<0.01\)** by ANOVA and Tukey’s post test. Data are represented as mean and S.E.M. of three independent experiments. (c) Representative images of three independent experiments of acidine orange vital staining of U87 cells after 24 h of 1 \(\mu\)M VP-16 treatment; experimental groups as indicated. Acid vesicles are stained in red and total cells are represented by the nuclear-cytoplasmic green staining. Scale bar = 10 \(\mu\)m. (d) Transmission electron microscopy of VP-16-treated cells (1 \(\mu\)M for 24 h) shows the presence of content filled autophagic vacuoles (white arrows) in both non-silenced and silenced groups (siRNA-Neg plus VP-16 and siRNA-RB plus VP-16 groups, respectively). Although non-silenced cells also show several clear vacuoles of which most of the content has been degraded (black arrows), RB-silenced cells show mainly content-filled vacuoles (white arrows), possibly indicating autophagic flux blockage. Control cells (siRNA-Neg) show vacuoles with hardly any content. N, nucleus. Scale bar = 6 \(\mu\)m.
knockout increases DNA double-strand breaks induced by cisplatin or camptothecin treatment due to ongoing replication following chemotherapeutic treatment in RB-deficient cells. Here we show that this property of RB is also valid for VP-16 treatment and is kept in GBM cells, indicating once again that the presence of RB in tumor cells can influence the response to chemotherapy. We believe that an increase in DNA double-strand breaks, followed by RB knockdown, leads to higher levels of apoptosis following VP-16 treatment in GBM cells, as we also observed an increase in p53 phosphorylation at serine 15 residue and in VP-16-induced apoptosis. However, our results showed that RB knockdown also potentiated VP-16 cytotoxicity in the absence of p53 activation, showing that in different genetic backgrounds RB knockdown may act differently to increase VP-16-induced apoptosis.

The literature shows that autophagy may serve as a resistance mechanism in tumor cells, including GBM, as the pharmacological inhibition of its final steps increases chemotherapy-induced apoptosis. It has been postulated that upon stress stimuli, autophagy is able to remove mitochondria that had undergone outer membrane permeabilization, which would explain autophagy’s role on apoptosis inhibition. Here we showed that RB protein positively regulates the progression of VP-16-induced autophagic flux in GBM cells, and that at the same time it reduces VP-16-induced apoptosis. Huang et al. have shown that RB cleavage by caspase and bafilomycin 1, an inhibitor of the vacuolar type H(+)ATPase, treatment had the same effect on TNF-α-induced cell death, which suggests that RB might have a role on acidification and/or vesicle trafficking. However, to our knowledge, this is the first report to show RB participation in the interplay between autophagy and apoptosis in the context of tumor resistance to therapy. Besides, we also show effectively that RB participates in the process of autophagosome/lysosome fusion.

Our work gives a valuable contribution not only to the understanding of the molecular mechanisms driving GBM resistance to VP-16, but also adds molecular regulation information to the body of knowledge constructed with numerous works, showing that in a universal manner

---

**Figure 6** RB knockdown blocked VP-16-induced autophagic flux. (a) Representative confocal images of three independent experiments showing LAMP 1 – a lysosome marker (red) and LC3 – a autophagosome marker (green) colocalization in U87 cells after 24 h of 1 μM VP-16 treatment; experimental groups as indicated. Nuclei were stained with DAPI. Scale bar = 20 μm. (a’) Higher magnifications of siRNA-Neg plus VP-16 and siRNA-RB plus VP-16 conditions images. Arrows indicate cells with LAMP 1/LC3 colocalization. Arrowheads indicate cells without LAMP 1/LC3 colocalization. Scale bar = 20 μm. (b) Histogram showing the LAMP1/LC3 colocalization rate in U87 cells after 24 h of VP-16 treatment. Experimental groups as indicated. ***P < 0.005 by ANOVA and Tukey’s post test. Data are represented as mean and S.E.M. of three independent experiments. (c) Histogram shows fold changes of p62 levels over siRNA-Neg control group; after 24 h of VP-16 treatment of U87 cells; experimental groups as indicated. ***P < 0.005 by ANOVA and Tukey’s post test. Data are represented as mean and S.E.M. of three independent experiments. (d) Histogram shows fold changes VRK1 levels over siRNA-Neg control group; after 24 h of VP-16 treatment of U87 cells; experimental groups as indicated. *P < 0.05 by ANOVA and Tukey’s post test. Data are represented as mean and S.E.M. of three independent experiments. (e) Representative p62 and VRK1 immunoblots for U87 cells 24 h post-VP-16 treatment; experimental groups as indicated. α-Tubulin was used as loading control.
pharmacological inhibition of autophagic flux improves chemotherpay-induced apoptosis.51–53

Finally, the study of the molecular regulation of GBM resistance to VP-16 is of utmost importance, as the effectiveness of VP-16 treatment is restricted because of its use in high doses, and consequent side effects, in recurrent GBM patients.6 Our work gives consistent evidences that the presence of hyperphosphorylated RB in GBM cells contributes to VP-16 resistance. This information creates the possibility of the adoption of a low-dosage VP-16 therapy for patients with non-RB-expressing GBM, providing a more effective therapy, with fewer side effects. Our results showing that the U373 cell line, which expresses low levels of RB, is more sensitive to VP-16 treatment compared with the other cell lines corroborates this possibility. For RB-expressing GBM patients, the combination of RB silencing with VP-16 would be one way of improving, in the future, the effectiveness of the therapy. Currently, there is a clinical trial involving the use of RNAi in GBM patients, which attests the possibility of RNAi as therapeutic strategy for GBM, despite the need for improved delivery efficacy.54

Materials and Methods

Cell culture. Human GBM cell lines used were as follows: U87MG, which does not express the CDK inhibitor p1655 A172 (expresses RB and wild-type p53); T98G (mutant for p53) and U373MG (expresses low levels of RB) are originally from ATCC, Manassas, VA, USA; GBM95 was isolated in our laboratory through the biopsy of a recurrent GBM tumor.56 All cell lines were previously described.55 Cultures were maintained at 37°C and 5% CO2.

Transmission electron microscopy. Cells were fixed in fixative solution containing 2.5% glutaraldehyde and 0.1 M sodium cacodylate buffer pH 7.2 for 2 h at RT. The pellet was then washed twice with 0.1 M cacodylate buffer and post fixed in 1% OsO4 solution in 0.1 M cacodylate buffer for 40 min at RT. Following three washes in PBS, the pellet was dehydrated with ethanol (35–100%; 15 min for each step) and infiltrated overnight in a mix 2:1 ethanol: EPON. The next day, the mixture was changed to 1:1 ethanol: EPON for 24 h, and then the sample was embedded in EPON and placed at 60°C for 48 h for polymerization. Sections were made using a Leica Ultramicrotome (Buffalo Grove, IL, USA) at 60 nm, collected using copper grids and counterstained with uranyl acetate and lead citrate. Images were taken using a Zeiss EM900 transmission electron microscope (Zeiss, Oberkochern, Germany).

Immunofluorescence. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.25% Triton X-100. Non-specific binding was blocked with 5% bovine serum albumin and the samples were then incubated with anti-LAMP1 conjugated to Cy3 (Sigma, St Louis, MO, USA) or anti-AELEXA fluor-568 (Invitrogen), or anti-rabbit ALEXA fluor-488 (Invitrogen) for 2 h at room temperature. Nuclei were counterstained with 4’,6-diamidino-2-phenylindole dithylocarbodil (DAPI).

Fluorescence images were captured with the Nikon Eclipse TE300 microscope (Nikon do Brasil LTDA, São Paulo, Brazil) equipped with a CoolSNAP-Proc color, ROPER SCIENTIFIC Photometrics digital camera (Nikon do Brasil LTDA), or using a confocal microscope (Leica TCS-SP5) equipped with a ×63 NA 1.40 oil-immersion objective. Cleaved caspase-3 immunostaining images were captured in Operetta High Content Imaging System (Perkin Elmer, Waltham, MA, USA) and quantification of the percentage of cleaved caspase-3-positive cells was done by the Harmony High Content Imaging and Analysis Software (Perkin Elmer).

To quantify H2A-X staining, we used the ratio of fluorescence intensity (Image J software),57 over the total cell number (DAPI). The ratio obtained in siRNA-Neg control was used to normalize other experimental groups. Experiments were carried out in duplicates; for every experimental condition, at least 500 cells were counted.

Cell counting was done by using the Embryonic Stem Cell Counter (ESCC) software.58

MTT cytotoxicity assay. For VP-16 dose–response curves, within the last 2 h of VP-16 treatment, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT – Sigma) was added to the media at a final concentration of 0.5 mg/mL. Cells were then resuspended and lysed in dimethyl sulfoxide. Absorbance was measured at 570 nm. Mean absorbance obtained for control condition was considered 100% of cell viability.
Supravital cell staining with acridine orange for acid vesicle formation. Cytoplasm and nuclei of acridine orange-stained cells normally fluoresce bright green and dim red, respectively, whereas acinar compartments fluoresce bright red. The intensity of red fluorescence is proportional to the degree of acidity.43 Acridine orange solution (1 mg/ml; Sigma) was used to stain cells for 20 min. Images of staining were obtained with the Nikon Eclipse TE300 microscope, as described above. To quantify acid vesicle formation, we used the ratio of red fluorescence intensity (ImageJ software) over total cell number. The ratio obtained for siRNA-Neq condition was used to normalize other experimental groups. Cell counting was done using the ESCC software.58

Statistical analysis. GraphPad-Prism software was used to analyze data and plot curves. Data are represented as mean and S.E.M. ANOVA (analysis of variance) test and Tukey’s post test were used to determine statistical significance of difference between data sets. P < 0.05 was considered statistically significant.

Conflict of Interest. The authors declare no conflict of interest.

Acknowledgements. We thank Rosinilde Carvalho do Holanda Afonso and Anna Carolina Carvalho da Fonseca for technical assistance. We thank Dr. Jean Wang (UCSD) and Dr Leonardo Travassos (UFRJ) for donating the T98G cell line. This work was supported by the National Council for Scientific and Technological Development (CNPq), by the Brazilian Federal Agency for Support and Evaluation of Higher Education (CAPES), by the Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ) and Cancer Foundation (Oncobiology Program UFRJ).

1. Alves TR, Lima FR, Kahn SA, Lobo D, Dubois LG, Soletti R et al. Glialbloma cells: a heterogeneous and fatal tumor interacting with the parenchyma. Life Sci 2011; 89: 532–539.
2. Lima FR, Kahn SA, Soletti RC, Dias L, Alves TR, da Fonseca AC et al. Glialbloma: therapeutic challenges, what lies ahead. Biochim Biophys Acta 2012; 1826: 338–349.
3. Maier EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK et al. Glioblastoma: genetics and biology of a grave matter. Gene Dev 2001; 15: 1311–1333.
4. Adamson C, Kanu OO, Mehta AI, Di C, Mattox AK et al. Targeting autophagy potentiates therapeutic challenges, what lies ahead. Am J Hematol 2012; 6: 500–510.
5. Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD et al. Enhanced laminin organization. J Biol Chem 2004; 279: 7383–7393.
6. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG et al. Malignant gliomas: genetics and biology of a grave matter. Nat Rev Cancer 2008; 8: 714–724.
7. Campos B, Fan F, Farahmi M, Ernst A, Zeppernick F, Taggcher KE et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010; 16: 2715–2728.
8. Chau BN, Bird J, Wason K, Cardiff RD, Van Meir EG, Brat DJ, Mastrogiannis GM et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061–1066.
9. Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC et al. Histone H2AX phosphorylation on serine 139. EMBO J. 2002; 21: 571–573.
10. Wang JY, Wagner LA. Autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 2007; 14: 548–558.
11. Guo XL, Li D, Hu F, Song JR, Zhang SS, Deng WJ et al. Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocellular carcinoma cells. Cell Death Differ 2012; 20: 171–179.
12. Liu J, Han SL, Fan X. Modulating autophagy: a strategy for cancer therapy. Chinese J Cancer 2011; 30: 655–668.
13. Filipp-Chiela EC, Villore ES, Zamin LL, Lenz G. Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS One 2011; 6: e20849.

14. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The course of etoposide- induced apoptosis and proliferation inhibition in hepatocarcinoma cells. Oncogene 2000; 19: 2171–2178.
15. Chau BN, Pan CW, Wang JY. Separation of anti-proliferation and anti-apoptotic functions of retinoblastoma protein through targeted mutations of its A/B domain. PLoS One 2006; 1: e62.
16. Chau BN, Lu B, Long L, Chen L, Huang Q, Liang Z. Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer 2011; 129: 2270–2273.
17. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kerieg SM et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488: 522–526.
18. Chinn DW, Domenech C, Catabio R, Solcis G, Pfeiffer M. S-phase lengthening induced by p16(NK4a) overexpression in malignant cells with wild-type pRb and p53. Cell Cycle 2010; 9: 3288–3296.
19. Faira J, Romao L, Martins S, Alves T, Mendes FA, de Faria GP et al. Interactive properties of human glioblastoma cells with brain neurons in culture and neuronal modulation of glial laminin organization. Diff Res Biol Diversity 2006; 74: 562–572.
20. Kipnis DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
21. Kipnis DJ, Abdala FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
22. Kipnis DJ, Abdala FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
23. Kipnis DJ, Abdala FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
24. Kipnis DJ, Abdala FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
25. Kipnis DJ, Abdala FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
26. Kipnis DJ, Abdala FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
27. Kipnis DJ, Abdala FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
28. Kipnis DJ, Abdala FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
29. Kipnis DJ, Abdala FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
30. Kipnis DJ, Abdala FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.
46. Crighton D, Wilkinson S, O’Prey J, Syed N, Smith P, Harrison PR et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126: 121–134.
47. Valbuena A, Castro-Obregon S, Lazo PA. Downregulation of VRK1 by p53 in response to DNA damage is mediated by the autophagic pathway. PLoS One 2011; 6: e17320.
48. Bosco EE, Mayhew CN, Hennigan RF, Sage J, Jacks T, Knudsen ES. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res 2004; 32: 25–34.
49. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741–752.
50. Huang X, Masselli A, Frisch SM, Hunton IC, Jiang Y, Wang JY. Blockade of tumor necrosis factor-induced Bid cleavage by caspase-resistant Rb. J Biol Chem 2007; 282: 29401–29413.
51. Kanematsu S, Uehara N, Miki H, Yoshizawa K, Kawanaka A, Yuri T et al. Autophagy inhibition enhances sulforaphane-induced apoptosis in human breast cancer cells. Anticancer Res 2010; 30: 3381–3390.
52. Amaravadi RK, Yu D, Lum J, Bui T, Christophorou MA, Evan GI et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117: 326–336.
53. Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 2012; 131: 548–557.
54. Rolle K, Nowak S, Wyszko E, Nowak M, Zukiel R, Piestrzyniewicz R et al. Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biol Ther 2010; 9: 396–406.
55. Patru C, Romao L, Varlet P, Coulombel L, Raponi E, Cadusseau J et al. CD133, CD15/ SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer 2010; 10: 66.
56. Wang JY, Knudsen ES, Welch PJ. The retinoblastoma tumor suppressor protein. Adv Cancer Res 1994; 64: 25–85.
57. Rasband WS. ImageJ. US National Institutes of Health: Bethesda, MD, USA, 1997. Available from: http://imagej.nih.gov/ij/.
58. Geisa M, Faustino MG, Carlos J, de Lucena P, Stevens Rehen. Embryonic Stem Cell Counter 2009. Available from: http://escc.inf.puc-rio.br/index.html.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/.

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)